Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-a drugs: An Italian multicenter study

Ennio Lubrano, Fabio Massimo Perrotta, Antonio Marchesoni, Salvatore D'Angelo, Roberta Ramonda, Olga Addimanda, Ignazio Olivieri, Leonardo Punzi, Carlo Salvarani

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. To investigate the possibility of achieving partial remission (PR) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) versus ankylosing spondylitis (AS) treated with anti-tumor necrosis factor (TNF)-α antagonists, such as adalimumab (ADA), etanercept (ETN), and infliximab (IFX), in a real clinical practice setting. The Assessment of SpondyloArthritis international Society (ASAS) 20, ASAS40, and Ankylosing Spondylitis Disease Activity Score were also calculated. Methods. A retrospective study was conducted in patients with axSpA treated with ADA, ETN, and IFX from 2000 to 2013. All patients fulfilled the ASAS or the modified New York criteria. PR was reached when the score was <20 mm (on a visual analog scale of 0-100 mm) in each of these domains: (1) patient global assessment, (2) pain, (3) function, and (4) inflammation. Results. A total of 321 patients with axSpA were treated. Among them, 62 were nr-axSpA while the remaining 259 were AS. Log-rank test to compare survival curves showed that the probability of obtaining PR in nr-axSpA and AS during treatment with anti-TNF-&alpha was not significantly different. At 12 weeks of exposure to the first anti-TNF-α drug, PR was achieved in 7 patients with nr-axSpA (11.3%) and in 68 patients with AS (26.2%). Conclusion. Our results, obtained from clinical practice, showed that PR is an achievable target of anti-TNF-α treatment in nr-axSpA. The PR rate, as a reliable indicator of sustained effectiveness, is similar in nr-axSpA and in AS.

Original languageEnglish
Pages (from-to)258-263
Number of pages6
JournalJournal of Rheumatology
Volume42
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Keywords

  • Ankylosing spondylitis
  • Anti-TNF-αdrugs
  • Nonradiographic axial spondyloarthritis
  • Remission

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Fingerprint Dive into the research topics of 'Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-a drugs: An Italian multicenter study'. Together they form a unique fingerprint.

Cite this